Triptorelin (Decapeptyl®)

DRUG2 trials

Sponsors

Ipsen

Conditions

Prostate Cancer

Phase 2

Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

TerminatedNCT00444639

IpsenProstate Cancer

Start: 2007-02-28End: 2008-06-30Updated: 2019-11-22

Phase 3

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

CompletedNCT01020448

IpsenProstate Cancer

Start: 2009-11-30End: 2013-06-30Updated: 2019-01-30

Related Papers

Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy.

2016-03-2317 citations